KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas
J. A. Heward, L. Koniali, A. D'Avola, K. Close, A. Yeomans, M. Philpott, J. Dunford, T. Rahim, A. F. Al Seraihi, J. Wang, K. Korfi, S. Araf, S. Iqbal, F. Bewicke-Copley, E. Kumar, , J. Fitzgibbon
This study shows that inhibiting KDM5 demethylases restores H3K4 methylation and reactivates genes in KMT2D mutant lymphomas, offering a potential therapeutic strategy.
bioRxiv · Jun 30, 2020Cancer Biology